Therapeutic interventions for disease progression in Huntington's disease
T Mestre, J Ferreira, MM Coelho… - … of systematic reviews, 2009 - cochranelibrary.com
T Mestre, J Ferreira, MM Coelho, M Rosa, C Sampaio
Cochrane database of systematic reviews, 2009•cochranelibrary.comBackground Huntington's disease (HD) is an autosomal dominant neurodegenerative
disease with an average onset between the fourth and fifth decade of life; it leads to death
15 to 20 years after the onset of symptoms. Although several drugs seem effective in
controlling the incapacitating manifestations of HD, no specific therapy is known. The
present review aims at analysing the best available data on therapeutic interventions
investigated with the goal of modifying the progression of the disease as measured in terms …
disease with an average onset between the fourth and fifth decade of life; it leads to death
15 to 20 years after the onset of symptoms. Although several drugs seem effective in
controlling the incapacitating manifestations of HD, no specific therapy is known. The
present review aims at analysing the best available data on therapeutic interventions
investigated with the goal of modifying the progression of the disease as measured in terms …
Background
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease with an average onset between the fourth and fifth decade of life; it leads to death 15 to 20 years after the onset of symptoms. Although several drugs seem effective in controlling the incapacitating manifestations of HD, no specific therapy is known. The present review aims at analysing the best available data on therapeutic interventions investigated with the goal of modifying the progression of the disease as measured in terms of survival, disability or progression of HD core symptoms.
Objectives
cochranelibrary.com